Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

This study has been completed.
Information provided by:
VA Office of Research and Development Identifier:
First received: July 3, 2001
Last updated: January 20, 2009
Last verified: December 2004
This study is designed to evaluate the potential beneficial effects of estrogen on cognitive function of women with Alzheimer's Disease.

Condition Intervention Phase
Alzheimer's Disease
Drug: estrogen
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Alzheimer's Disease and Aging: Therapeutic Potential of Estrogen

Resource links provided by NLM:

Further study details as provided by VA Office of Research and Development:

Study Start Date: April 1998
Estimated Study Completion Date: March 2001

Ages Eligible for Study:   50 Years to 90 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
  • Post menopausal women with alzheimer's disease
  • free of any major medical or neurological disease,
  • medically safe to be treated with estrogen.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00018343

United States, Washington
VA Puget Sound Health Care System
Lakewood, Washington, United States, 98493-5000
Sponsors and Collaborators
VA Office of Research and Development
Investigator: Suzanne Craft, Ph.D
Investigator: Laura Baker, Ph.D
Investigator: Murray Raskind, M.D.
  More Information

No publications provided Identifier: NCT00018343     History of Changes
Other Study ID Numbers: AGCG-007-97F
Study First Received: July 3, 2001
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Nervous System Diseases
Neurodegenerative Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs processed this record on December 01, 2015